| Title : 7-substituted tacrine derivatives: Overcoming tacrine's hepatotoxicity while enhancing therapeutic potential in Alzheimer's disease - Korabecny_2025_J.Neurol.Sci_480_ |
| Author(s) : Korabecny J , Svobodova B , Novak M , Horak M , Soukup O |
| Ref : Journal of the Neurological Sciences , 480 : , 2025 |
|
Abstract :
Tacrine (THA), the first FDA-approved acetylcholinesterase inhibitor for Alzheimer's disease (AD), was discontinued in 2013 due to its severe hepatotoxicity. This toxicity is largely attributed to the metabolic conversion of THA to 7-hydroxytacrine (7-OH-THA), which undergoes further transformation into a reactive quinone methide species, leading to glutathione depletion and liver damage |
| PubMedSearch : Korabecny_2025_J.Neurol.Sci_480_ |
| PubMedID: |
| Inhibitor | 3-Hydroxytacrine |
Korabecny J, Svobodova B, Novak M, Horak M, Soukup O (2025)
7-substituted tacrine derivatives: Overcoming tacrine's hepatotoxicity while enhancing therapeutic potential in Alzheimer's disease
Journal of the Neurological Sciences
480 :
Korabecny J, Svobodova B, Novak M, Horak M, Soukup O (2025)
Journal of the Neurological Sciences
480 :